Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …

Osteosarcoma Osteosarcoma, which is most common in people 10 to 30 years of age, is
generally treated with resection and adjuvant chemotherapy. Detection of gene …

Improving the survival of patients with osteosarcoma has long proved challenging, although
the treatment of this disease is on the precipice of advancement. The increasing feasibility of …

Osteosarcoma is the most frequent primary bone tumor with poor prognosis. Through RNA-
sequencing of 100,987 individual cells from 7 primary, 2 recurrent, and 2 lung metastatic …

Osteosarcoma (OS) is the most frequent primary bone cancer in children and adolescents
and the third most frequent in adults. Many inherited germline mutations are responsible for …

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …

Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–
3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate …

Comparative oncology clinical trials play an important and growing role in cancer research
and drug development efforts. These trials, typically conducted in companion (pet) dogs …

Abstract Ectodomain phosphatase/phosphodiesterase-1 (ENPP1) is overexpressed on
cancer cells and functions as an innate immune checkpoint by hydrolyzing extracellular …

Purpose The objective of this study was to investigate the antitumor activity, targeting
capability, and mechanism of the developed nanodrug consisting of doxorubicin and …